PMID- 7895594
OWN - NLM
STAT- MEDLINE
DCOM- 19950426
LR  - 20131121
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 16
IP  - 5
DP  - 1994 Sep
TI  - [Therapeutic effect of carboplatin and etoposide combinative therapy on 123 lung 
      cancer cases].
PG  - 384-6
AB  - The clinical effect of Carboplatin and Etoposide (CE regimen) on 58 cases of 
      small cell lung cancer (SCLC) and 65 cases of non small cell lung cancer (NSCLC) 
      was observed, and its influence on immunity was investigated simultaneously. The 
      result showed that the overall response rate of SCLC group was 72.4% (42/58). 
      Among them, the response rate of primary treatment was 81.0% (31/38), and that of 
      secondary treatment was 30.0% In NSCLC group, the response rate of primary 
      treatment was 30.0% (6/20). In NSCLS group, the rate of primary treatment was 
      22.9% (8/35), and that of secondary treatment was 13.3% (4/30). From the result 
      it was found that the response rate of primary treatment was higher than that of 
      secondary treatment, and that the main side-effect of CE regimen was mild 
      leukopenia, and the other side-effects included gastrointestinal symptoms, 
      alopecia and mild hepatic function changes. The influence of CE regimen on 
      immunity was temporary, and will soon recover. Repeating the regimen is 
      reasonable. So we think that CE regimen is one of the best regimens for SCLC 
      patients.
FAU - Shi, T Z
AU  - Shi TZ
AD  - PLA General Hospital, Beijing.
FAU - Yan, J L
AU  - Yan JL
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - BG3F62OND5 (Carboplatin)
RN  - JET protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carboplatin/administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/immunology
MH  - Carcinoma, Small Cell/*drug therapy/immunology
MH  - Etoposide/administration & dosage/adverse effects
MH  - Humans
MH  - Leukopenia/chemically induced
MH  - Lung Neoplasms/*drug therapy/immunology
MH  - Middle Aged
MH  - T-Lymphocyte Subsets/drug effects
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 1994 Sep;16(5):384-6.